Updated Jul 16, 2026
Evans John M. has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $7.76M.
John M. Evans is the CEO of Beam Therapeutics Inc., a biotechnology company focused on precision genetic medicines. Under his leadership, the company aims to develop innovative treatments for serious diseases using proprietary base editing technology.
| Role | Insider |
|---|---|
| Notability | 50/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-01 | BEAM | Beam Therapeutics Inc. | S — Open-market sale | 1.9K | $34.84 | $66K |
| 2026-07-01 | BEAM | Beam Therapeutics Inc. | S — Open-market sale | 23.1K | $34.26 | $791K |
| 2026-07-01 | BEAM | Beam Therapeutics Inc. | M — Option exercise | 25.0K | $1.03 | $26K |
| 2026-07-01 | BEAM | Beam Therapeutics Inc. | S — Open-market sale | 11.6K | $35.91 | $416K |
| 2026-07-01 | BEAM | Beam Therapeutics Inc. | S — Open-market sale | 13.4K | $35.13 | $472K |
| 2026-07-01 | BEAM | Beam Therapeutics Inc. | M — Option exercise | 6.3K | $1.03 | $7K |
| 2026-07-01 | BEAM | Beam Therapeutics Inc. | M — Option exercise | 18.7K | $0.67 | $13K |
| 2026-04-06 | BEAM | Beam Therapeutics Inc. | S — Open-market sale [10b5-1] | 30.1K | $24.58 | $739K |
| 2026-04-01 | BEAM | Beam Therapeutics Inc. | A — Grant or award [10b5-1] | 90.0K | $0.00 | |
| 2026-04-01 | BEAM | Beam Therapeutics Inc. | S — Open-market sale [10b5-1] | 25.0K | $22.76 | $569K |
| 2026-04-01 | BEAM | Beam Therapeutics Inc. | M — Option exercise [10b5-1] | 25.0K | $0.67 | $17K |
| 2026-04-01 | BEAM | Beam Therapeutics Inc. | S — Open-market sale [10b5-1] | 25.0K | $22.37 | $559K |
| 2026-04-01 | BEAM | Beam Therapeutics Inc. | M — Option exercise [10b5-1] | 25.0K | $0.67 | $17K |
| 2026-02-02 | BEAM | Beam Therapeutics Inc. | S — Open-market sale [10b5-1] | 2.9K | $29.00 | $84K |
| 2026-02-02 | BEAM | Beam Therapeutics Inc. | S — Open-market sale [10b5-1] | 22.1K | $28.27 | $625K |
| 2026-02-02 | BEAM | Beam Therapeutics Inc. | M — Option exercise [10b5-1] | 25.0K | $0.67 | $17K |
| 2026-02-02 | BEAM | Beam Therapeutics Inc. | S — Open-market sale [10b5-1] | 8.7K | $29.74 | $258K |
| 2026-02-02 | BEAM | Beam Therapeutics Inc. | S — Open-market sale [10b5-1] | 16.3K | $29.19 | $477K |
| 2026-02-02 | BEAM | Beam Therapeutics Inc. | M — Option exercise [10b5-1] | 5.7K | $0.67 | $4K |
| 2026-02-02 | BEAM | Beam Therapeutics Inc. | M — Option exercise [10b5-1] | 19.3K | $0.67 | $13K |
John M. Evans is the CEO of Beam Therapeutics Inc., a biotechnology company focused on precision genetic medicines. Under his leadership, the company aims to develop innovative treatments for serious diseases using proprietary base editing technology.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 14 open-market sales ($7.76M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Evans John M. profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.